Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REINFORCE
2024-514312-27-00Phase 4Authorised
- Sponsor
- Rigshospitalet
- Start
- Jan 2025
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of ciprofloxacin, fluconazole, nitrofurantoin, pivmecillinam, amoxicillin and 5 more in bacterial disease (2 arms), sponsored by Rigshospitalet. Primary endpoint: 90-day infection-related hospital readmission rate. Planned start Jan 2025; status: authorised.
02
Drugs
ciprofloxacinfluconazolenitrofurantoinpivmecillinamamoxicillin
03
Conditions
bacterial disease
Beyond the preview
Go deeper on 2024-514312-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514312-27-00.